


Hybrid AF™ Convergent Therapy

The Hybrid AF Convergent Therapy is a minimally invasive cardiac ablation that combines the expertise of cardiac surgeons and electrophysiologists.



Professional Education Program Overview

PROGRAM OFFERINGS

PEER-TO-PEER DISCUSSIONS WITH PHYSICIAN FACULTY

- Connect with Hybrid AF Convergent Clinic HCP (physicians, service line administrators, OR staff, EP lab staff) either in person or virtually to discuss clinical questions and initial experiences.

CASE OBSERVATION

- Visit a Hybrid AF Convergent Therapy program to observe experienced EPs and CT surgeons collaborate in a live surgical case.

REIMBURSEMENT SUPPORT

- Attend prior authorization discussion with third-party consultant.

BEATING HEART HANDS-ON TRAINING

- Join a comprehensive, hands-on experience performing the Hybrid AF Convergent Therapy Approach safely and effectively.
 - **Cadaver Lab:** Attend a lab at one of our eight contracted facilities.
 - **Mobile Cadaver Lab:** The lab comes to a location near you.
 - **Synthetic Tissue Beating Heart Model:** This cadaver lab in a box is a lifelike model that can be used almost anywhere.

HOSPITAL STAFF TRAINING

- This day-long training for nursing units, which covers the entire perioperative patient continuum, helps prepare for the program start.

PROCTOR SUPPORT

- A physician or clinical education specialist provides in-person guidance for your hospital's Hybrid AF Convergent Program. Please contact your AtriCure representative two weeks prior to the scheduled case so an appropriate proctor can be assigned.

ACCREDITED COURSE

- **Hybrid AF Convergent Therapy in Cardiac Ablation (A Clinical Program Guide):** One CEU contact hour is provided.

NATIONAL TRAINING COURSE: HEART TEAM

- This collaborative one-day program includes didactic and hands-on experience for EPs, Surgeons, and APPs.

ON-DEMAND DIGITAL TOPICS

- Hear from physicians about key topics.

COMPREHENSIVE, ONGOING PROGRAM SUPPORT

- AtriCure encourages continued program support by scheduling collaborative peer-to-peer meetings with your Hybrid AF Convergent team to review initial case experiences. (Meetings are designed for physicians, service line administrators, and/or EP lab staff.)
- AtriCure's experienced clinical education team is available to support physicians and staff with in-service trainings, practice runs before the first case, and ongoing case support.
- AtriCure provides a toolbox of training materials such as a physician training guide, hospital staff in-service guide, animations, live surgical videos, and a simulator hands-on training model.

Hybrid AF™ Convergent Therapy Professional Education Program Overview

The Hybrid AF Convergent Therapy is a minimally invasive cardiac ablation that combines the expertise of cardiac surgeons and electrophysiologists.

INTERESTED IN A TRAINING OPPORTUNITY? Contact your local AtriCure representative or visit <https://www.AtriCure.com/Healthcare-Professionals/Education-Training>

Epi-Sense® Guided Coagulation System

U.S. Indications: The Epi-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients (1) who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and (2) in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions. **Contraindications** include patients with Barrett's Esophagitis, left atrial thrombus, a systemic infection, active endocarditis, or a localized infection at the surgical site at the time of surgery. **Adverse Events:** Reported adverse events associated with epicardial ablation procedure may include, but are not limited to, the following: pericardial effusion/cardiac tamponade, pericarditis, excessive bleeding, phrenic nerve injury, stroke/TIA/neurologic complication. Please review the Instructions for Use for a complete listing of contraindications, warnings, precautions and potential adverse events located at the following AtriCure web address: <https://www.AtriCure.com/Epi-Sense-Coagulation-Device>. **Warnings:** Physicians should consider post-operative anti-inflammatory medication to decrease the potential for post-operative pericarditis, and/or delayed post-procedure inflammatory pericardial effusions. Physicians should consider post-procedural imaging (i.e. 1-3 weeks post-procedure) for detection of post-procedure inflammatory pericardial effusions. **Precautions:** Precautionary measures should be taken prior to considering treatment of patients: (1) Deemed to be high risk and who may not tolerate a potential delayed post-procedure inflammatory pericardial effusion. (2) Who may not be compliant with needed follow-ups to identify potential safety risks. To ensure patients undergoing treatment with the Epi-Sense device are well informed, the benefits, potential risks and procedural outcomes associated with the Epi-Sense Hybrid Convergent procedure should be discussed with the patient. Physicians should document accordingly in the medical record. Qualified operators are physicians authorized by their institution to perform surgical sub-xyphoid pericardial access. The coagulation devices should be used by physicians trained in the techniques of minimally invasive endoscopic surgical procedures and in the specific approach to be used. Operators should undergo training on the use of Epi-Sense device before performing the procedure. Safety and effectiveness of concomitant left atrial appendage closure was not evaluated in the CONVERGE study. Follow-up should be conducted at approximately 30 days post-procedure to monitor for signs of delayed onset pericarditis or pericardial effusion. **Rx Only.**